Author Archives: Warren Woessner

Regeneron v. Mylan, “It Ain’t Necessarily So.”

Posted on April 27, 2025 by Warren Woessner

Regeneron v. Mylan, appeal nos. 2024-2058, 2024-2147 (Fed. Cir., March 5, 2025) is the most recent appeal in a long line of Hatch-Waxman suits filed by Regeneron to block generic versions of its VEGF antagonist (or “trap”) EYLEA®, that is … Continue reading →

Posted in Inherency | Leave a comment

Obviousness-type double patenting in the Age of the Twenty-Year Term and Patent Term Adjustment

Posted on March 31, 2025 by Warren Woessner

Obviousness-type double patenting (ODP) attempts to prevent the term of a “reference patent” claiming an obvious variant of a parent patent to exceed the term of the parent. This fulfills the mandate of the patent statute of “one patent per … Continue reading →

Posted in Obviousness | Tagged Obviousness-type double patenting in the Age of the Twenty-Year Term and Patent Term Adjustment | Leave a comment

Allergan v. Sun – A Glidant Slips Past the Written Description Requirement

Posted on August 31, 2024 by Warren Woessner

The most interesting part of this decision by the Fed. Cir. (No. 24- 1061, Aug. 13, 2024) is that the court was faced with an argument by Sun that Allergan’s claims in U.S. Pat. No.11,311,516 et al. are invalid as … Continue reading →

Posted in Litigation Issues, Uncategorized, Written Description Requirements (WDR) | Tagged Allergan v Sun, Federal Circuit, glidant, pharma patents, Written Description Requirements | Leave a comment

The Chisum Patent Academy Makes an Appearance in Cincinnati

Posted on August 5, 2024 by Warren Woessner

When I was in law school, we had but one treatise to use, the weighty “Choate on Patents” (1973). A number of “horn books” have appeared since, including the authoritative “Chisum on Patents” and his wife’s weighty treatise “Mueller on … Continue reading →